TriSalus Life Sciences Inc.(TLSI)正式启动名为Predictt的前沿临床研究项目。该试验旨在深入评估其创新的压力驱动给药技术对肝脏肿瘤的治疗效果。
通过这项突破性技术,研究人员将探索如何利用压力调控机制优化药物在肝部病灶区域的靶向输送效率。该临床试验的推进标志着公司在肿瘤介入治疗领域迈出重要一步。
TriSalus Life Sciences Inc.(TLSI)正式启动名为Predictt的前沿临床研究项目。该试验旨在深入评估其创新的压力驱动给药技术对肝脏肿瘤的治疗效果。
通过这项突破性技术,研究人员将探索如何利用压力调控机制优化药物在肝部病灶区域的靶向输送效率。该临床试验的推进标志着公司在肿瘤介入治疗领域迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.